The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Sourcebio gave little detail and no real forward guidance. Hopefully we will give both. As for the re rate, who knows if and when that will happen but I'm still hopeful (perhaps unwisely) of a positive run up to results and beyond.
I must be mad but I'm still excited. If the RNS reads anything like the blurb for the European sales job then the ship could finally set sail: Due to the ongoing success and growth of Novacyt, we are now looking to strengthen our teams in key areas of North and South Europe.
We have amazing opportunities for driven sales professionals, who have a passion for taking exceptional market leading products to market and want to build a substantial career in a growing successful business
CO, meat on the bone, yes, entirely black box no - https://novacyt.com/wp-content/uploads/2021/06/Novacyt-2020-Full-Year-Results-Strategy-update-Final-website-version-for-29.06.2021-1.pdf (p11-17). Yes a few more specifics would be nice especially about the things we already know about but we know broadly the direction of travel. Hopefully they will put some positive numbers (and spin) on the strategy and then away we go.
Hi, discussed in the investor presentation (from about 28 mins): https://novacyt.com/investor-event-2021/
32bn in 2020, 36bn in 2021, est. 93bn in 2030. All things being equal, our revenue at that point should be at least £300m.
I know we are all fixated on what happens come the end of Jan but worthwhile remembering that regardless of how much the co. choose to tell us, we are well placed in a growing market so it ought to be a matter of when, not if.
https://www.globenewswire.com/news-release/2022/01/07/2363168/0/en/Point-of-Care-Diagnostics-Market-Size-to-Hit-USD-93-21-Bn-by-2030.html
Interestingly they also smashed their own forecast. Now I know there are different listing rules and we repeated our guidance so close to year but still shows a beat is more than possible (p.s I'm not saying it will happend and certainly not banking on it!)
Thanks Sir D, could be huge if it becomes more widely disseminated. For ease of reference for those that have not seen, the final paragraph of their RNS reads:
The performance of other marketed SARS-CoV-2 antigen lateral flow tests may well be adversely affected by the Omicron variant. This mutant is already the dominant SARS-CoV-2 variant in many countries and may soon be the dominant variant globally. We therefore believe it is essential that similar Omicron sensitivity studies be performed on all SARS-CoV-2 antigen tests and the results communicated to ensure the public can have confidence in the results these tests generate."
Related linkedin post (can't find any Novacyt links)
https://www.linkedin.com/posts/tatamedicalanddiagnostics_omicron-covid-tata-activity-6884486688157106176-1TUN
Hi B2 , genuine qu, what do you perceive your really bad situation to look like? If this is a plan to take the co. private and keep positive info on the D/L then surely any buyer would still have to pay a premium to current sp. The question would be how low can the buyer get it for but in all likelihood it will be quite a bit north from where we are so the really bad is not that bad (although clearly nowhere near as good as most of us are hoping for)..
Omicron will not be the end despite what the politicians say and the market is lapping up. Whatever happens with the rules today / next week / next month our covid goods will be in demand for a while yet. Now if only DA would tell us about the non covid plan
https://twitter.com/erlichya/status/1478628925718814722?t=OeCdgIHldIWNuRub76kubQ&s=19
I'm not a technical trader but find this website useful. https://www.barchart.com/stocks/quotes/ALNOV.FP/opinion
We've gone from a 100% sell to a 40% buy in a couple of months. One more month and we will be a 100% buy. Patience my friends.